Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate





CML, event-free survival, EFS, first-line, imatinib


Objective: Chronic myeloid leukemia (CML) prognostication at the time of diagnosis is critical to determine the intensity of initial treatment. Event-free survival (EFS) has become a prominent concept of prognosis in the patients with chronic phase CML (CML-CP). The aim of this study is to assess the prognostic impact of bone marrow (BM) and peripheral blood (PB) cellular components, in correlation with the clinical parameters.

Materials and Methods: One hundred forty-three patients with CML-CP on the front-line imatinib mesylate therapy were recruited into this study. Clinical and laboratory characteristics, therapeutic responses were recorded. Sokal, Euro/Hasford, The EUropean Treatment Outcome Study (EUTOS) and The EUTOS long-term survival (ELTS) scores were calculated for the studied patients.

Results: Median follow-up time was 84 (IQR: 54-125) and median front-line therapeutic duration was 56 (IQR:23-89) months. Five-year EFS rate was 62.3% (95% CI: 53.9-70.7). The blast percentage in the BM, EUTOS scores, and basophil percentage in PB were related with the poor therapeutic outcomes in frontline therapy (p=0.002, p=0.002 and p=0.042, respectively). Although Sokal risk classification showed that the intermediate class had a higher event risk compared to the low-risk class (p=0.001), the predictive association disappeared in high-risk classes.

Conclusion: EUTOS score system has better predictive capability for front-line imatinib therapy comparing with other indices. Higher blast percentage in BM and increased basophil percentage in PB are independent risk factors, adversely related with EFS in patients with CML.


Download data is not yet available.




How to Cite

Eyüpoğlu ND, Çınar OE, Aksu S, Büyükaşık Y, Sayınalp N, Demiroğlu H, Göker H, Özcebe Oİ, Haznedaroğlu İC. Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate. Acta Medica [Internet]. 2022 Jun. 15 [cited 2024 Jun. 23];53(3):277-83. Available from: https://actamedica.org/index.php/actamedica/article/view/745



Original Article